Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chinook Therapeutics Inc (NQ: KDNY )

24.77 -0.33 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 544,532
Open 25.13
Bid (Size) 23.62 (1)
Ask (Size) 25.93 (1)
Prev. Close 25.10
Today's Range 24.32 - 25.47
52wk Range 15.08 - 27.44
Shares Outstanding 66,889,369
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:KDNY Investor Notice: Investigation over Potential Securities Laws Violations by Chinook Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 06/01/2023 -- Chinook Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Bragar Eagel & Squire, P.C. Is Investigating Integra, and Chinook and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-2.63%
-2.63%
1 Month
+17.34%
+17.34%
3 Month
+6.26%
+6.26%
6 Month
+9.80%
+9.80%
1 Year
+51.22%
+51.22%

More News

Read More
CHINOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Chinook Therapeutics, Inc. on Behalf of Chinook Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Where Chinook Therapeutics Stands With Analysts
Via Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Recap: Chinook Therapeutics Q1 Earnings
Via Benzinga
Chinook Therapeutics Trial Pause: Unfortunate But Analyst Reassures No Damage To Value Drivers
Via Benzinga
Chinook Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Chinook Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
KDNY INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Chinook Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – KDNY
From The Rosen Law Firm, P.A.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023
Via Benzinga
Where Chinook Therapeutics Stands With Analysts
Via Benzinga
Chinook Therapeutics's Return On Capital Employed Insights
Via Benzinga
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook Popped
Via Investor's Business Daily
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Chinook Secures Orphan Drug Status From European Commission For Kidney Disease Drug
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.